Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7Z4S

Crystal structure of SARS-CoV-2 Mpro in complex with cyclic peptide GM4 including unnatural amino acids.

Summary for 7Z4S
Entry DOI10.2210/pdb7z4s/pdb
Descriptor3C-like proteinase nsp5, Macrocyclic peptide inhibitor, DI(HYDROXYETHYL)ETHER, ... (7 entities in total)
Functional Keywordsprotease, unknown function
Biological sourceSevere acute respiratory syndrome coronavirus 2
More
Total number of polymer chains4
Total formula weight71373.41
Authors
Primary citationMiura, T.,Malla, T.R.,Owen, C.D.,Tumber, A.,Brewitz, L.,McDonough, M.A.,Salah, E.,Terasaka, N.,Katoh, T.,Lukacik, P.,Strain-Damerell, C.,Mikolajek, H.,Walsh, M.A.,Kawamura, A.,Schofield, C.J.,Suga, H.
In vitro selection of macrocyclic peptide inhibitors containing cyclic gamma 2,4 -amino acids targeting the SARS-CoV-2 main protease.
Nat.Chem., 15:998-1005, 2023
Cited by
PubMed Abstract: γ-Amino acids can play important roles in the biological activities of natural products; however, the ribosomal incorporation of γ-amino acids into peptides is challenging. Here we report how a selection campaign employing a non-canonical peptide library containing cyclic γ-amino acids resulted in the discovery of very potent inhibitors of the SARS-CoV-2 main protease (M). Two kinds of cyclic γ-amino acids, cis-3-aminocyclobutane carboxylic acid (γ) and (1R,3S)-3-aminocyclopentane carboxylic acid (γ), were ribosomally introduced into a library of thioether-macrocyclic peptides. One resultant potent M inhibitor (half-maximal inhibitory concentration = 50 nM), GM4, comprising 13 residues with γ at the fourth position, manifests a 5.2 nM dissociation constant. An M:GM4 complex crystal structure reveals the intact inhibitor spans the substrate binding cleft. The γ interacts with the S1' catalytic subsite and contributes to a 12-fold increase in proteolytic stability compared to its alanine-substituted variant. Knowledge of interactions between GM4 and M enabled production of a variant with a 5-fold increase in potency.
PubMed: 37217786
DOI: 10.1038/s41557-023-01205-1
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.7 Å)
Structure validation

227111

数据于2024-11-06公开中

PDB statisticsPDBj update infoContact PDBjnumon